Ideaya Biosciences Begins Trial of IDE196, Xalkori in Uveal Melanoma Patients

Source: genomeweb, January 2021

San Francisco-based Ideaya Biosciences on Tuesday said that it has dosed its first uveal melanoma patient in a clinical trial evaluating its PKC inhibitor IDE196 with Pfizer’s cMET inhibitor crizotinib (Xalkori).

Ideaya, which develops precision oncology drugs for patients selected using molecular diagnostics, is evaluating the IDE196-crizotinib combination in metastatic uveal melanoma patients following results from preclinical research demonstrating synergistic activity between the two agents.

Mick O’Quigley, Ideaya’s VP and head of development operations, said in a statement that the company decided to advance the combination to clinical trials based on translational research that included evaluation of cMET expression in samples from metastatic uveal melanoma patients.